文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

减量糖皮质激素联合利妥昔单抗诱导ANCA相关血管炎缓解的随机临床试验

Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项4期多中心开放标签随机非劣效性试验纳入140例新诊断、无严重肾小球肾炎或肺泡出血的ANCA相关血管炎患者,比较减量泼尼松龙(0.5 mg/kg/d)联合利妥昔单抗与高剂量泼尼松龙(1 mg/kg/d)联合利妥昔单抗的疗效与安全性。6个月时减量组缓解率71.0%,高剂量组69.2%,差异1.8个百分点(单侧97.5%CI -13.7至∞),满足非劣效界值-20个百分点;减量组严重不良事件和严重感染发生率更低。

要点

  • 减量激素联合利妥昔单抗在6个月缓解率上非劣效于高剂量方案。
  • 减量组严重不良事件发生率18.8%,低于高剂量组的36.9%。
  • 减量组严重感染发生率7.2%,低于高剂量组的20.0%。

核心结论

  • 在新诊断且无严重肾小球肾炎或肺泡出血的ANCA相关血管炎患者中,减量糖皮质激素联合利妥昔单抗诱导6个月缓解的效果非劣效于高剂量糖皮质激素联合利妥昔单抗。

关键数值与推荐

  • 主要终点为6个月缓解率,预设非劣效界值为-20个百分点。
  • 减量组方案:泼尼松龙0.5 mg/kg/d联合利妥昔单抗375 mg/m2/wk共4剂;高剂量组方案:泼尼松龙1 mg/kg/d联合利妥昔单抗。

临床怎么用

  • 对于新诊断且无严重肾小球肾炎或肺泡出血的ANCA相关血管炎患者,可考虑采用减量糖皮质激素联合利妥昔单抗诱导缓解,以降低严重不良事件和严重感染风险。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究仅在日本进行,结果的外推性需谨慎。
  • 排除了严重肾小球肾炎或肺泡出血患者,结论不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The current standard induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis is the combination of high-dose glucocorticoids and cyclophosphamide or rituximab. Although these regimens have high remission rates, they are associated with considerable adverse events presumably due to high-dose glucocorticoids. OBJECTIVE: To compare efficacy and adverse events between a reduced-dose glucocorticoid plus rituximab regimen and the standard high-dose glucocorticoid plus rituximab regimen in remission induction of ANCA-associated vasculitis. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 4, multicenter, open-label, randomized, noninferiority trial. A total of 140 patients with newly diagnosed ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage were enrolled between November 2014 and June 2019 at 21 hospitals in Japan. Follow-up ended in December 2019. INTERVENTIONS: Patients were randomized to receive reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab (375 mg/m2/wk, 4 doses) (n = 70) or high-dose prednisolone (1 mg/kg/d) plus rituximab (n = 70). MAIN OUTCOMES AND MEASURES: The primary end point was the remission rate at 6 months, and the prespecified noninferiority margin was -20 percentage points. There were 8 secondary efficacy outcomes and 6 secondary safety outcomes, including serious adverse events and infections. RESULTS: Among 140 patients who were randomized (median age, 73 years; 81 women [57.8%]), 134 (95.7%) completed the trial. At 6 months, 49 of 69 patients (71.0%) in the reduced-dose group and 45 of 65 patients (69.2%) in the high-dose group achieved remission with the protocolized treatments. The treatment difference of 1.8 percentage points (1-sided 97.5% CI, -13.7 to ∞) between the groups met the noninferiority criterion (P = .003 for noninferiority). Twenty-one serious adverse events occurred in 13 patients in the reduced-dose group (18.8%), while 41 occurred in 24 patients in the high-dose group (36.9%) (difference, -18.1% [95% CI, -33.0% to -3.2%]; P = .02). Seven serious infections occurred in 5 patients in the reduced-dose group (7.2%), while 20 occurred in 13 patients in the high-dose group (20.0%) (difference, -12.8% [95% CI, -24.2% to -1.3%]; P = .04). CONCLUSIONS AND RELEVANCE: Among patients with newly diagnosed ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage, a reduced-dose glucocorticoid plus rituximab regimen was noninferior to a high-dose glucocorticoid plus rituximab regimen with regard to induction of disease remission at 6 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02198248.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021. PMID: 34061144. doi:10.1001/jama.2021.6615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。